AC Immune SA

IPO

Precision medicine for neurodegenerative diseases

Public · Lausanne, Switzerland · Founded 2003 · $100.1M raised

Headquarters
Lausanne
Employees
51–200
Founded
2003
Business Model
B2B
Total Funding
$100.1M
Last Round
$43.5M Private EquityDec 2016
Rounds
4
Type
Public

About

AC Immune is a clinical-stage biopharmaceutical company emerging as a global leader in precision medicine to diagnose, treat and prevent neurodegenerative diseases. Since AC Immune's foundation in 2003, its staff has developed pioneering scientific and clinical expertise in the understanding and treatment of neurodegeneration. Its cutting-edge technology platforms, SupraAntigen and Morphomer, are the engines for a diverse pipeline of clinical and preclinical product candidates, with scientific excellence validated through collaborations with Takeda, Janssen, Life Molecular Imaging and Lilly.

Summary

AC Immune SA is a Biotech company based in Lausanne, Switzerland, founded in 2003. It has raised $100.1M in total across 4 rounds, most recently a $43.5M Private Equity round in Dec 2016. Investors include Goldman Sachs, Morgan Stanley and SVB Leerink.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Private EquityPrivate EquityDec 2016

Sign up to see all 5 rounds

Series C through Private Equity — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

AC Immune SA on Indexed.vc
<a href="https://indexed.vc/companies/ac-immune-sa"><img src="https://indexed.vc/api/badge/company/ac-immune-sa" alt="AC Immune SA on Indexed.vc" width="260" height="76" /></a>